TheraVet SA (ALVET.PA)
EUR 0.11
(-0.46%)
EUR 0.11
(-0.46%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1 Million EUR | 11.54% |
| 2022 | 897.05 Thousand EUR | -1.38% |
| 2021 | 909.56 Thousand EUR | 30.11% |
| 2020 | 699.1 Thousand EUR | 100.18% |
| 2019 | 349.24 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 994.65 Thousand EUR | -0.59% |
| 2024 Q2 | 994.65 Thousand EUR | 0.0% |
| 2023 Q4 | 1 Million EUR | 0.0% |
| 2023 Q2 | 849.55 Thousand EUR | 0.0% |
| 2023 Q1 | 849.55 Thousand EUR | -5.3% |
| 2023 FY | 1 Million EUR | 11.54% |
| 2023 Q3 | 1 Million EUR | 17.78% |
| 2022 Q1 | 969.72 Thousand EUR | 6.61% |
| 2022 Q4 | 897.05 Thousand EUR | 0.0% |
| 2022 Q3 | 897.05 Thousand EUR | -7.49% |
| 2022 Q2 | 969.72 Thousand EUR | 0.0% |
| 2022 FY | 897.05 Thousand EUR | -1.38% |
| 2021 Q4 | 909.56 Thousand EUR | 0.0% |
| 2021 Q1 | 734.53 Thousand EUR | 5.07% |
| 2021 Q2 | 734.53 Thousand EUR | 0.0% |
| 2021 Q3 | 909.56 Thousand EUR | 23.83% |
| 2021 FY | 909.56 Thousand EUR | 30.11% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 699.1 Thousand EUR | 100.18% |
| 2020 Q3 | 699.1 Thousand EUR | 16.59% |
| 2020 Q4 | 699.1 Thousand EUR | 0.0% |
| 2020 Q2 | 599.61 Thousand EUR | 0.0% |
| 2019 FY | 349.24 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | 9.119% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 97.761% |
| Adocia SA | 4.54 Million EUR | 77.96% |
| Aelis Farma SA | 2.04 Million EUR | 51.143% |
| Biophytis S.A. | 3.11 Million EUR | 67.837% |
| Advicenne S.A. | 15.89 Million EUR | 93.705% |
| genOway Société anonyme | 5.51 Million EUR | 81.871% |
| IntegraGen SA | 642.28 Thousand EUR | -55.789% |
| Medesis Pharma S.A. | 1.2 Million EUR | 16.617% |
| Neovacs S.A. | 650 Thousand EUR | -53.938% |
| NFL Biosciences SA | 39.2 Thousand EUR | -2452.353% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 77.032% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | 48.958% |
| Sensorion SA | 1.24 Million EUR | 19.366% |
| Theranexus Société Anonyme | 2.46 Million EUR | 59.337% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 74.33% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 85.511% |
| argenx SE | 15.35 Million EUR | 93.483% |
| BioSenic S.A. | 15.57 Million EUR | 93.575% |
| Celyad Oncology SA | 902 Thousand EUR | -10.931% |
| DBV Technologies S.A. | 4.52 Million USD | 77.892% |
| Galapagos NV | 4.94 Million EUR | 79.761% |
| Genfit S.A. | 62.25 Million EUR | 98.393% |
| GeNeuro SA | 6.49 Million EUR | 84.588% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -190.872% |
| Innate Pharma S.A. | 30.6 Million EUR | 96.731% |
| Inventiva S.A. | 25.61 Million EUR | 96.094% |
| MaaT Pharma SA | 5.42 Million EUR | 81.556% |
| MedinCell S.A. | 52.8 Million EUR | 98.105% |
| Nanobiotix S.A. | 41.66 Million EUR | 97.598% |
| Onward Medical N.V. | 16.3 Million EUR | 93.864% |
| Oryzon Genomics S.A. | 3.45 Million EUR | 71.002% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 97.182% |
| Oxurion NV | 117 Thousand EUR | -755.213% |
| Pharming Group N.V. | 123.65 Million EUR | 99.191% |
| Poxel S.A. | 40.14 Million EUR | 97.507% |
| GenSight Biologics S.A. | 1.04 Million EUR | 4.523% |
| Transgene SA | 17 Thousand EUR | -5785.876% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.965% |
| Valneva SE | 132.76 Million EUR | 99.246% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |